Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

JAMA Internal Medicine ◽

10.1001/jamainternmed.2020.2922 ◽

2020 ◽

Vol 180 (12) ◽

pp. 1696

Author(s):

Colette DeJong ◽

Camlyn Masuda ◽

Randi Chen ◽

Dhruv S. Kazi ◽

R. Adams Dudley ◽

...

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Out Of Pocket Costs

Download Full-text

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

JAMA Network Open ◽

10.1001/jamanetworkopen.2020.20969 ◽

2020 ◽

Vol 3 (10) ◽

pp. e2020969

Author(s):

Jing Luo ◽

Robert Feldman ◽

Scott D. Rothenberger ◽

Inmaculada Hernandez ◽

Walid F. Gellad

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Receptor Agonists ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Out Of Pocket Costs

Download Full-text

PHP23 THE IMPACT OF MEDICARE PART D ON PRESCRIPTION VOLUME AND OUT-OF-POCKET COSTS OF MEDICALLY NECESSARY DRUGS

Value in Health ◽

10.1016/j.jval.2011.02.095 ◽

2011 ◽

Vol 14 (3) ◽

pp. A15-A16

Author(s):

B. Sepulveda ◽

J. Doyle ◽

C. White

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Prescription Volume ◽

Out Of Pocket Costs

Download Full-text

Abstract 4765: The impact of the Medicare Part D donut hole closure on use and out-of-pocket costs for aromatase inhibitors

10.1158/1538-7445.am2018-4765 ◽

2018 ◽

Author(s):

Ilana Graetz ◽

Janeane N. Anderson ◽

Cameron M. Kaplan

Keyword(s):

Aromatase Inhibitors ◽

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Hole Closure ◽

Out Of Pocket Costs

Download Full-text

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D

Diabetes Care ◽

10.2337/dc19-1294 ◽

2020 ◽

Vol 43 (4) ◽

pp. e50-e51 ◽

Author(s):

Chien-Wen Tseng ◽

Camlyn Masuda ◽

Randi Chen ◽

Daniel M. Hartung

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Out Of Pocket Costs

Download Full-text

Medicare Part D out-of-pocket costs, net present value of a PhD, and health literacy and self-care

Journal of the American Pharmacists Association ◽

10.1331/japha.2011.11523 ◽

2011 ◽

Vol 51 (3) ◽

pp. 448

Author(s):

L. Douglas Ried

Keyword(s):

Health Literacy ◽

Net Present Value ◽

Self Care ◽

Medicare Part D ◽

Medicare Part ◽

Present Value ◽

Part D ◽

Out Of Pocket Costs

Download Full-text

PHP48 THE EFFECTS OF NICE HTA'S ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES

Value in Health ◽

10.1016/s1098-3015(10)66288-2 ◽

2008 ◽

Vol 11 (6) ◽

pp. A376-A377 ◽

Author(s):

B Sepulveda ◽

N Horowicz-Mehler ◽

JJ Doyle

Keyword(s):

United States ◽

Medicare Part D ◽

The United States ◽

Retail Price ◽

Medicare Part ◽

Part D ◽

Volume Average ◽

Prescription Volume ◽

Out Of Pocket Costs

Download Full-text

Association of Medicare Part D Medication Out-of-Pocket Costs with Utilization of Statin Medications

Health Services Research ◽

10.1111/1475-6773.12022 ◽

2012 ◽

Vol 48 (4) ◽

pp. 1311-1333 ◽

Author(s):

Pinar Karaca-Mandic ◽

Tami Swenson ◽

Jean M. Abraham ◽

Robert L. Kane

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Out Of Pocket Costs

Download Full-text

Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D

JAMA Cardiology ◽

10.1001/jamacardio.2019.2223 ◽

2019 ◽

Vol 4 (8) ◽

pp. 828 ◽

Author(s):

Colette DeJong ◽

Dhruv S. Kazi ◽

R. Adams Dudley ◽

Randi Chen ◽

Chien-Wen Tseng

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Out Of Pocket Costs

Download Full-text

Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D

JAMA Oncology ◽

10.1001/jamaoncol.2021.5433 ◽

2021 ◽

Author(s):

Thomas J. Hwang ◽

Xuanzi Qin ◽

Nancy L. Keating ◽

Haiden A. Huskamp ◽

Stacie B. Dusetzina

Keyword(s):

Medicare Part D ◽

Medicare Part ◽

Cancer Drugs ◽

Part D ◽

Pass Through ◽

Out Of Pocket Costs

Download Full-text

Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

JAMA ◽

10.1001/jama.2018.7316 ◽

2018 ◽

Vol 320 (9) ◽

pp. 931 ◽

Author(s):

Jinoos Yazdany ◽

R. Adams Dudley ◽

Grace A. Lin ◽

Randi Chen ◽

Chien-Wen Tseng

Keyword(s):

Rheumatoid Arthritis ◽

Medicare Part D ◽

Medicare Part ◽

Part D ◽

Out Of Pocket Costs

Download Full-text